Novavax Advances Science Supporting Protein-based Vaccine Technology at IDWeek 2023 and World Vaccine Congress Europe 2023

At IDWeek, Novavax will present data on key COVID-19 vaccine attributes that drive people's vaccine choices, and clinical data from two studies comparing its Omicron BA.1 and BA.5 variant vaccines to its prototype COVID-19 vaccine's ability to induce superior neutralizing antibody responses to BA.1 and BA.5 viruses in individuals previously vaccinated with mRNA vaccines. At IDWeek, Novavax will present data on key COVID-19 vaccine attributes that drive people's vaccine choices, and clinical...

At IDWeek, Novavax will present data on key COVID-19 vaccine attributes that drive people's vaccine choices, and clinical data from two studies comparing its Omicron BA.1 and BA.5 variant vaccines to its prototype COVID-19 vaccine's ability to induce superior neutralizing antibody responses to BA.1 and BA.5 viruses in individuals previously vaccinated with mRNA vaccines.

At WVC EU, Novavax will showcase data from its Vaccine Impact on Productivity real-world study investigating the burden and impact of vaccine reactogenicity (solicited adverse local/systemic side effects), its Phase 2b/3 Hummingbird™ global clinical trial evaluating its prototype vaccine in children aged six through 11 years as well as its CIC vaccine candidate.

Novavax poster presentations during IDWeek:   

12:15-13:30pm (EST)
BCEC Poster Hall
Poster: 1371 

12:15-13:30pm (EST)
BCEC Poster Hall
Poster: 2337 

 

Novavax oral presentations during WVC EU: 

13:45pm (CET)

Room 4

14:00pm (CET)

Room 4

10:30am (CET)

Room 5

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines too help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information. 

Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Ali Chartan
240-720-7804
media@novavax.com

Logo - https://mma.prnewswire.com/media/1506866/NovavaHigh_Res_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/novavax-advances-science-supporting-protein-based-vaccine-technology-at-idweek-2023-and-world-vaccine-congress-europe-2023-301952812.html